Scientific Advisory Board


Chaitan Khosla, Ph.D., Chairman
Director of Stanford ChEM-H, and Professor of Chemistry & Chemical Engineering, Stanford University

Dr. Khosla has served as a member of our board of directors since October 2014. Dr. Khosla was the scientific founder and a member of the Board of Directors of Alvine Pharmaceuticals from 2005 until 2016. Prior to Alvine Pharmaceuticals, Dr. Khosla founded and was a director of Kosan Biosciences, from 1995 until it was acquired by Bristol-Myers Squibb in 2008. Dr. Khosla has been a Professor of Chemical Engineering and Chemistry at Stanford University since 2001 and has been a faculty member since 1992. Since 2013, he has served as the founding Director of Stanford ChEM-H. Dr. Khosla is an elected member of the American Academy of Arts & Sciences and the National Academy of Engineering. He is the recipient of several awards, including the 1999 Alan T. Waterman award by the National Science Foundation, the 1999 Eli Lilly Award in biological chemistry and the 2000 ACS Award in Pure Chemistry. Dr. Khosla is the author of over 300 publications and is an inventor on numerous patents. Dr. Khosla received a Ph.D. from the California Institute of Technology.

Back to top

Charles S. Craik, Ph.D.
Professor in the Departments of Pharmaceutical Chemistry, Cellular & Molecular Pharmacology, and Biochemistry & Biophysics, University of California at San Francisco (UCSF)

Dr. Craik is a Professor in the Departments of Pharmaceutical Chemistry, Cellular & Molecular Pharmacology and Biochemistry & Biophysics at the University of California at San Francisco and is also the founder and Director of the Chemistry and Chemical Biology Graduate Program. Dr. Craik co-founded Catalyst Biosciences, Inc. in 2003 and served as its Chairman of the Board and President. He joined the UCSF faculty in 1985. He serves on advisory panels for the National Institutes of Health, the National Science Foundation, the National Academy of Sciences and the Department of Energy. Dr. Craik serves as an Associate Editor of the Journal Protein Engineering and has co-authored two books. He has organized several international meetings on topics including Protein Engineering, Drug Discovery and The Biology of Proteolysis, and is the recipient of the 2016 Emil Thomas Kaiser Award from the Protein Society. He has published over 200 research articles on various biochemical topics. He focuses on the Chemical Biology of proteolytic enzymes and their natural inhibitors. Dr. Craik received his Ph.D. in Chemistry from Columbia University in New York and carried out his postdoctoral research at UCSF with Dr. William Rutter.

Back to top

Jason G. Cyster, Ph.D.
Professor in the Department of Microbiology and Immunology, University of California at San Francisco (UCSF), and Investigator, Howard Hughes Medical Institute

Dr. Cyster is a Professor in the Department of Microbiology and Immunology at the University of California, San Francisco, an Investigator of the Howard Hughes Medical Institute, and a member of the National Academy of Sciences. Cyster is an Immunologist recognized for his work on the cues guiding immune cell movements in lymphoid organs and for defining the mechanism of lymphocyte egress from tissues. He is also known for his use of real-time 2-photon microscopy to study immune cell migration and interaction dynamics within tissues during antibody responses. Cyster was born in Western Australia and grew up on a cattle farm in the south of the state. He graduated from the University of Western Australia with a degree in Biochemistry and Microbiology and from the University of Oxford with a D.Phil. in Immunology in 1992. He was a postdoctoral fellow in immunology at Stanford University School of Medicine and he joined the faculty at the University of California, San Francisco in 1995.

Back to top

Mark Gallop, Ph.D.
Chief Scientific Officer, Nurix, Inc.

Dr. Gallop serves as the Chief Scientific Officer at Nurix, Inc. Prior to joining Nurix, he was Senior Vice President of Research and XenoPort, Inc., a company he co-founded in 1999 with the mission of improving the clinical utility of medicines by exploiting active transport mechanisms to optimize pharmacokinetic properties of drugs. While at XenoPort, his team discovered Horizant, a prodrug of gabapentin that was approved by the FDA in 2011 and the MHW in Japan in 2012 for the treatment of restless legs syndrome. Previously, Dr. Gallop was Senior Director of Combinatorial Chemistry at Affymax. He is recognized as an early pioneer and international expert in solid-phase combinatorial chemistry and was a recipient of the ACROS award of the Belgian Organic Synthesis Symposium in 1996 for his outstanding contributions to this field. He is an inventor on more than 100 issued or pending U.S., and PCT patents and an author of over 60 manuscripts in peer-reviewed journals. In 1994, he co-authored a landmark review of the then-emerging field of combinatorial chemistry that has subsequently become one of the most highly cited papers in chemistry. After undergraduate studies in New Zealand, he obtained his Ph.D. degrees in inorganic chemistry from the University of Cambridge and was a Lindemann postdoctoral fellow in the laboratories of Profs. Peter G. Schultz and Robert G. Bergman at the University of California, Berkeley.

Back to top

K.C. Nicolaou, Ph.D.
Harry C. and Olga K. Wiess Professor of Chemistry, Rice University

Dr. Nicolaou studied chemistry at the University of London, where he earned his Bachelor of Science and doctorate. In 1972, he moved to the United States and, after postdoctoral appointments at Columbia University and Harvard University, joined the faculty at the University of Pennsylvania. There, he rose through the ranks to become the Rhodes-Thompson Professor of Chemistry. In 1989, he accepted joint appointments at the University of California, San Diego, where he was professor of chemistry, and The Scripps Research Institute, where he was the Darlene Shiley Professor of Chemistry and chairman of the Department of Chemistry. In 1996, he was appointed Aline W. and L.S. Skaggs Professor of Chemical Biology in The Skaggs Institute for Chemical Biology, The Scripps Research Institute. In May 2013, Dr. Nicolaou joined Rice University as the Harry C. and Olga K. Wiess Professor of Chemistry in the BioScience Research Collaborative.

He serves on the scientific advisory board for numerous scientific journals and is an advisor to several biotechnology and pharmaceutical companies. Dr. Nicolaou’s research interests include the chemistry, biology and medicine of natural and designed molecules. His group’s research activities are centered around the total synthesis of architecturally novel and biologically important natural products. He is the author or co-author of more than 725 publications, 67 patents and five books. Among K.C. Nicolaou’s awards and honors are the Wolf Prize in Chemistry (Israel), Schering Prize (Germany), the Aspirin Prize (Spain), the Max Tishler Prize Lecture (Harvard), the Yamada Prize (Japan), the Janssen Prize (Belgium), the Nagoya Medal (Japan), the Centenary Medal (Royal Society UK), the Paul Karrer Medal (Switzerland), the Inhoffen Medal (Germany), the Nichols Medal (USA), the Linus Pauling Medal (USA), the Esselen Award (USA), the ACS Award for Creative Work in Synthetic Organic Chemistry (USA), the ACS Guenther Award in Natural Products Chemistry (USA), the Nobel Laureate Signature Award, Tetrahedron Prize Award, the Benjamin Franklin Medal in Chemistry, and several honorary degrees. He is a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences and a member of the American Philosophical Society.

Back to top